Cargando…
Bispecific antibody-derived molecules to target persistent HIV infection
HIV infection persists despite durable and potent antiviral therapy. To target persistent HIV infection, one major strategy aims to induce HIV provirus expression using latency reversing agents and then eliminate these reservoir cells via immune responses enhanced by treatment with antibody-derived...
Autores principales: | Nordstrom, Jeffrey L., Ferrari, Guido, Margolis, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468498/ https://www.ncbi.nlm.nih.gov/pubmed/36111287 http://dx.doi.org/10.1016/j.jve.2022.100083 |
Ejemplares similares
-
Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART(®) Molecules
por: Tuyishime, Marina, et al.
Publicado: (2021) -
Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules
por: Pollara, Justin, et al.
Publicado: (2020) -
TCR-mimic bispecific antibodies to target the HIV-1 reservoir
por: Sengupta, Srona, et al.
Publicado: (2022) -
Treatments for persistent HIV infection: the road ahead
por: Margolis, David M
Publicado: (2010) -
Nanocell targeting using engineered bispecific antibodies
por: Taylor, Karin, et al.
Publicado: (2014)